Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3076226 · 1 trial · 2 indications
The MTD was defined as the highest dose tested that had less than 33% probability of causing a dose limiting toxicity (DLT).
| Arm | Type | Description |
|---|---|---|
| LY3076226 | EXPERIMENTAL | Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle. Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle. |
| Name | Type | Description |
|---|---|---|
| LY3076226 | DRUG | Administered IV |
Inclusion Criteria: * Have advanced or metastatic cancer and be an appropriate candidate for experimental therapy. * Part B: Have a diagnosis of bladder cancer. * Part B: Have alterations of FGFR3. * Have adequate organ function. * Have discontinued previous treatments for cancer and have reso...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY3076226 is an investigational small molecule being studied for the treatment of advanced or metastatic cancer. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is intended for patients with advanced cancer who are aged 18 years and older.
LY3076226 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company conducted a Phase 1 clinical trial of the drug in participants with advanced or metastatic cancer.
LY3076226 is in Phase 1 clinical development. A Phase 1 trial of the drug has been completed, but the drug remains investigational and has not received FDA approval. It is not yet available as a marketed therapy for cancer patients.
LY3076226 has been studied in one clinical trial, identified as NCT02529553, titled "A Study of LY3076226 in Participants With Advanced or Metastatic Cancer." This Phase 1 trial was completed and enrolled 25 participants in the United States and Canada.
LY3076226 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development. The drug has not been authorized for commercial use in any country.